Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis

doi:10.5246/jcps.2018.01.007

Abstract

Abstract:

There is no radical cure for ankylosing spondylitis, a chronic inflammation in joint, till now. Tumor necrosis factor-alpha (TNF-α) inhibitors can block the cascade in inflammatory chain and improve clinical symptom. Among these biological agents, three of them are marketed in China: etanercept, infliximab and adalimumab. Some of the research progresses between 2014 and 2016 are summarized including treatment application, side effects of drugs, and comprehensive research of TNF-α inhibitors.

Key words: Ankylosing spondylitis, TNF-α, Etanercept, Infliximab, Adalimumab

CLC Number:

R954

Supporting:

Zhou Linguang, Jiang Bin. Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(1): 59-63.

References

[1] Taurog, J.D.; Chhabra, A.; Colbert, R.A. Ankylosing Spondylitis and AxialSpondyloarthritis. N. Engl. J. Med. 2016, 374, 2563-2574.

[2] Hamilton, L.; Barkham, N.; Bhalla, A.; Brittain, R.; Cook, D.; Jones, G.; Mackay, K.; Marshall, D.; Marzo-Ortega, H.; Murphy, D.; Riddell, C.; Sengupta, R.; Siebert, S.; Van Rossen, L.; Gaffney, K. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosingspondylitis) with biologics. Rheumatology. 2017, 56, 313-316.

[3] Rheumatology, C.S. Guidelines for diagnosis and treatment of ankylosing spondylitis. Chin. J. Rheumatol. 2010, 14, 557-559.

[4] Anderson, J.J.; Baron, G.; van der Heijde, D.; Felson, D.T.; Dougados, M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis. Rheum. 2001, 44, 1876-1886.

[5] Braun, J.; van den Berg, R.; Baraliakos, X.; Boehm, H.; Burgos-Vargas, R.; Collantes-Estevez, E.; Dagfinrud, H.; Dijkmans, B.; Dougados, M.; Emery, P.; Geher, P.; Hammoudeh, M.; Inman, R.D.; Jongkees, M.; Khan, M.A.; Kiltz, U.; Kvien, T.; Leirisalo-Repo, M.; Maksymowych, W.P.; Olivieri, I.; Pavelka, K.; Sieper, J.; Stanislawska-Biernat, E.; Wendling, D.; Ozgocmen, S.; van Drogen, C.; van Royen, B.; van der Heijde, D. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 2011, 70, 896-904.

[6] Gorman, J.D.; Sack, K.E.; Davis, J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 2002, 346, 1349-1356.

[7] Reed, M.R.; Taylor, A.L. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008, 38, 781-789.

[8] NICE. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. 2016.

[9] Yates, M.; Hamilton, L.E.; Elender, F.; Dean, L.; Doll, H.; MacGregor, A.J.; Thomas, J.; Gaffney, K. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J. Rheumatol. 2015, 42, 1177-1185.

[10] Ye, Y.J.; W, C.C.; Qiu, Q.; Liang, L.Q. Maintenance of the therapeutic efficacy of etanercept in active ankylosing spondylitis patients when tapering its dosage. J. Practical. Med. 2016, 32, 2642-2645.

[11] Bessant, R.; Keat, A. How should clinicians manage osteoporosis in ankylosing spondylitis? J. Rheumatol. 2002, 29, 1511-1519.

[12] Li, H.; Li, Q.; Chen, X.; Ji, C.; Gu, J. Anti-tumor Necrosis Factor Therapy Increased Spine and Femoral Neck Bone Mineral Density of Patients with Active Ankylosing Spondylitis with Low Bone Mineral Density. J. Rheumatol. 2015, 42, 1413-1417.

[13] Arends, S.; Brouwer, E.; Efde, M.; van der Veer, E.; Bootsma, H.; Wink, F.; Spoorenberg, A. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin. Exp. Rheumatol. 2017, 35, 61-68.

[14] Jin, Q. Clinical observation of 90 cases of etanercept combined with Cloud G treatment of ankylosing spondylitis. J. Clin. Med. Pract. 2016, 20, 153-154.

[15] Ke, L. Clinical efficacy of etanercept combined with sulfasalazine in treatment of ankylosing spondylitis. Guide China Med. 2014, 12, 217-218.

[16] Sieper, J.; Lenaerts, J.; Wollenhaupt, J.; Rudwaleit, M.; Mazurov, V.I.; Myasoutova, L.; Park, S.; Song, Y.; Yao, R.; Chitkara, D.; Vastesaeger, N. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis, results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum. Dis. 2014, 73, 101-107.

[17] Lei, J.; Li, Z. Jia qiong. Clinical observation of 30 cases of Modified Simiao Pills combined with infliximab in the treatment of ankylosing spondylitis. Guid. J. Traditional Chin. Med. Pharm. 2015, 21, 74-76.

[18] Xiao, Y.Y.; Zhang, J.; Qiu, X.; Zhong, L.; Xiao, X.; Zhang, Y.Y.; Xie, J.J. Observation of the efficacy of infliximab and Bushen Tongbitai granules in the treatment of ankylosing spondylitis. Neimonggu J. Tradit. Chin. Med. 2015, 8, 62-63.

[19] Jia, J.T.; Wang, H.; Li, H.; Xue, X.P. Effect of Inflximab on Bone Metabolic Indices in Ankylosing Spondylitis. Chin. J. Allergy Clin. Immunol. 2014, 8, 278-282.

[20] Mease, P.; Sieper, J.; Van den Bosch, F.; Rahman, P.; Karunaratne, P.M.; Pangan, A.L. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015, 67, 914-923.

[21] Huang, F.; Gu, J.; Zhu P, Bao, C.; Xu, J.; Xu, H.; Wu, H.; Wang, G.; Shi, Q.; Andhivarothai, N.; Anderson, J.; Pangan, A.L. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis, results of a randomised, controlled trial. Ann Rheum. Dis. 2014, 73, 587-594.

[22] Paramarta, J.E.; Baeten, D.L. Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res. Ther. 2014, 16,

[23] Cantini, F.; Niccoli, L.; Goletti, D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J. Rheumatol. (Suppl.) 2014, 91, 47-55.
[24] Maxwell, L.J.; Zochling, J.; Boonen, A.; Singh, J.A.; Veras, M.M.; Tanjong Ghogomu, E.; Benkhalti Jandu, M.; Tugwell, P.; Wells, G.A. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane. Database Syst. Rev. 2015, 18, 23-30.